NCT05195008View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions
Healthy Volunteer
Interventions
DRUG

BIIB113

Administered as specified in the treatment arm.

DRUG

BIIB113-Matching Placebo

Administered as specified in the treatment arm.

DRUG

11^C]BIO-1819578

Administered as specified in the treatment arm.

Trial Locations (3)

14186

Karolinska Comprehensive Cancer Center - Studieenheten, Flemingsberg

NW10 7EW

Hammersmith Medicine Research, London

M23 9QZ

Medicines Evaluation Unit, Wythenshawe

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY